Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines. The identification of somatic mutations in JAK2, MPL and LNK in

read more>>

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments. It has been an unresolved question whether (i) combination treatment with the chemotherapeutic drug chlorambucil plus a monoclonal

read more>>

Multiple myeloma is the second most common hematological cancer. It is a cancer of the plasma cells and it accounts for approx. 1% of all cancers. At present, no cure is available. The 5-year relative survival rate for multiple myeloma is around 40% so there is a strong need for new treatment Dara

read more>>

Treatment for patients with multiple myeloma (MM) has improved over the last decade due to the introduction of new drugs such as lenalidomide and bortezomib. However, after receiving multiple treatments, MM patients often become resistant (refractory) to these drugs and have an average survival of

read more>>

Mast Therapeutics, Inc. announced the pricing of an underwritten public offering of 50,000,000 units, each unit consisting of a fixed combination of one share of common stock and one warrant to purchase 0.5 of a share of common stock, at a public offering price of $0.50 per unit. The units will not

read more>>

A rare genetic disease may be going to the dogs. About six in 100,000 babies are born with centronuclear myopathy, which weakens skeletal muscles so severely that children have trouble eating and breathing and often die before age 18. Now, by discovering a very similar condition in canines, The st

read more>>

People in Northland are rallying to support the family of a two-and-a-half-year-old Whangarei boy who is suffering from a rare illnessMostyn Baigent has a movement disorder known as anti-NMDA receptor encephalitisHis father Aaron says Mostyn was recently due to leave Starship Hospital, when it wa

read more>>

CAMBRIDGE, Mass. - Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan medicinal product designation from the European Commission for use in mesothelioma. The designation is to encourage

read more>>

San Francisco, CA, USA and Nes-Ziona, Israel - PROLOR Biotech, Inc., announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical

read more>>

BOUDRY, Switzerland - Celgene International Sàrl, a subsidiary of Celgene Corporation presented results from a randomized, placebo-controlled phase II trial in patients with Behçet’s disease (BD) at EULAR, the European Congress of Rheumatology annual meeting in MadridThe Company announced stat

read more>>